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This is an official guideline of the European Society of Gastrointestinal
Endoscopy (ESGE) and the European Society of Gastrointestinal and
Abdominal Radiology (ESGAR), published in Endoscopy and European
Radiology simultaneously. It addresses the clinical indications for the use
of computed tomographic colonography (CTC). A targeted literature
search was performed to evaluate the evidence supporting the use of
CTC. The Grading of Recommendations Assessment, Development and
Evaluation (GRADE) system was adopted to define the strength of
recommendations and the quality of evidence.
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1  ESGE/ESGAR recommend computed tomographic
    colonography (CTC) as the radiological examination
    of choice for the diagnosis of colorectal neoplasia.
    ESGE/ESGAR do not recommend barium enema in
    this setting (strong recommendation, high quality
    evidence).
Main recommendations
2  ESGE/ESGAR recommend CTC, preferably the same
    or next day, if colonoscopy is incomplete. Delay of CTC
    should be considered following endoscopic resection.
    In the case of obstructing colorectal cancer, preoperative
    contrast-enhanced CTC may also allow location or
    staging of malignant lesions (strong recommendation,
    moderate quality evidence).
3  When endoscopy is contraindicated or not possible,
    ESGE/ESGAR recommend CTC as an acceptable and
    equally sensitive alternative for patients with symptoms
    suggestive of colorectal cancer (strong recommenda-
    tion, high quality evidence).
4  ESGE/ESGAR recommend referral for endoscopic
    polypectomy in patients with at least one polyp
    6 mm in diameter detected at CTC. CTC surveillance
    may be clinically considered if patients do not undergo
    polypectomy (strong recommendation, moderate quali-
    ty evidence).
5  ESGE/ESGAR do not recommend CTC as a primary
    test for population screening or in individuals with a 
    positive first-degree family history of colorectal cancer
    (CRC). However, it may be proposed as a CRC screen-
    ing test on an individual basis providing the screenee is
    adequately informed about test characteristics, benefits,
    and risks (weak recommendation, moderate quality
    evidence).
Introduction
Colorectal cancer (CRC) is a major cause of morbidity and
mortality [1, 2]. CRC screening by fecal occult blood testing
(FOBT) has been shown to reduce CRC mortality [3, 4], and
is currently used in several European countries. Colonoscopy
is highly effective for detecting advanced neoplasia, and
endoscopic polypectomy reduces subsequent CRC-
specific incidence and mortality [5]. In Europe, colonos-
copy is mainly used to investigate FOBT-positive or
symptomatic patients, or as a preventive strategy in
those with increased CRC risk [6].
Computed tomographic colonography (CTC) is a minimal-
ly invasive imaging technique that is highly accurate for
detecting colorectal cancer (CRC) and adenomatous polyps.
The technique is standardized [7], and CTC is more easily
performed than barium enema. Evidence-based data suggest
that CTC is the natural replacement for barium enema and a
complementary rather than an alternative examination to co-
lonoscopy. However, the clinical scenarios for which CTC is
indicated remain unclear. To address this uncertainty – 20
years after the first presentation of CTC at a radiological
meeting [8] – the European Society of Gastrointestinal En-
doscopy (ESGE) and the European Society of Gastrointestinal
and Abdominal Radiology (ESGAR) decided to produce a
common guideline regarding indications for CTC in clinical
practice. Technical and quality issues of CTC have been
deliberately excluded from this work as these have already
been discussed separately [7].
Methods
The ESGE and ESGAR commissioned this Guideline (chairs
C.S. and A.L.) and invited the listed authors to participate in
the development of the Guideline. The key questions were
prepared by the coordinating team (C.S. and A.L.) and then
approved by the other members (see Appendix e1, available
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online). The coordinating team convened subgroup task
forces, each with one radiologist and one endoscopist lead,
and allocated the key questions to these task forces.
Each task force performed a systematic literature search to
prepare evidence-based statements on their assigned key ques-
tions. Medline, EMBASE and other databases were searched
including the following search terms as minimum: colon,
cancer or malignancy or neoplasm, and CTC. All articles
investigating CTC in symptomatic or screening contexts were
selected by inspecting the title and abstract. Hereditary colo-
rectal syndromes were excluded. After further exploration of
the content, each task force summarized the included articles
in a table of evidence (see Appendix e2, available online). All
selected articles were graded on level of evidence and strength
of recommendation according to the GRADE system [9, 10].
The literature searches were updated to September 2013.
Each task force prepared statements answering their
assigned key questions. The statements were discussed sub-
sequently and voted on during a face-to-face meeting of the
whole group held on 1 October 2013. In May 2014, a draft
prepared by the coordinating team was sent to all group
members for comment. After agreement on a final version,
the manuscript was reviewed by two experts selected by the
ESGE and ESGAR Governing Boards and then submitted to
the journals of ESGE and ESGAR.
This Guideline will be reviewed in 2019, or sooner if
relevant new evidence becomes available. Any updates to
the Guideline in the interim will be noted on the websites of
ESGE (http://www.esge.com/esge-guidelines.html) and
ESGAR (http://www.esgar.org).
Recommendations and statements
Evidence statements and recommendations are stated in
italics, key evidence statements and recommendations are in
bold.
CT colonography (CTC) and diagnosis of colorectal
neoplasia
ESGE/ESGAR recommend computed tomographic
colonography (CTC) as the radiological examination of choice
for the diagnosis of colorectal neoplasia. ESGE/ESGARdo not
recommend barium enema in this setting (strong recommen-
dation, high quality evidence).
Computed tomographic colonography (CTC) can be con-
sidered to be the best radiological test for the diagnosis of
colorectal cancer. Several randomized [11–13], multicenter
[14, 15], and single-center trials [16–18], and meta-analyses
[19–26], have shown that regarding accuracy for both
colorectal cancer (CRC) and large/advanced polyps, CTC is
similar to colonoscopy in symptomatic and asymptomatic
patients and is clearly superior to barium enema [11]. In a
recent randomized trial (the SIGGAR trial) [11, 13] compar-
ing CTC with colonoscopy and barium enema, the detection
rate for colorectal cancer or large polyps was significantly
higher in patients assigned to CTC than in those assigned to
barium enema (7.3% vs 5.6%, P < 0.039) but similar for
colonoscopy and CTC (11% for both procedures).
In a comparative study between colonoscopy and barium
enema [27], the sensitivity and specificity of barium enema
were respectively 38% and 86% for polyps of any size. In
another publication [28], using a 5-mm threshold, per-patient
sensitivity and specificity of barium enema were respectively
41% and 82%; at a threshold greater than 10 mm, these values
were respectively 48% and 90%.
In a meta-analysis comparing the performance of barium
enema with CTC [29] for detection of colorectal polyps
≥6 mm in average risk and high risk patients, CTC was more
specific and more sensitive than barium enema for large
polyps (≥10 mm) and small polyps (6–9 mm), in both per-
patient and per-polyp analysis. In the per-patient analysis,
CTC showed an incremental diagnostic yield in sensitivity
of 12.0% for polyps ≥10 mm and of 30.1% for polyps of 6–9
mm, and in specificity of 10.3% for polyps ≥10 mm.
Apart from better diagnostic performance, CTC is more
tolerable and acceptable to patients and delivers a lower
effective radiation dose than barium enema [30].
CT colonography following incomplete colonoscopy
ESGE/ESGAR recommend CT colonography (CTC), pref-
erably the same or next day, if colonoscopy is incomplete.
Delay of CTC should be considered following endoscopic
resection. In the case of obstructing colorectal cancer, pre-
operative contrast-enhanced CT colonography may also al-
low location or staging of malignant lesions. (strong recom-
mendation, moderate quality evidence).
Incomplete colonoscopy has been reported to occur in
10%–15% of all colonoscopies [31, 32], and it has been
associated with a higher risk of interval cancers in epidemio-
logical studies [33]. Incomplete colonoscopy may be ad-
dressed by repetition of colonoscopy or by radiological pro-
cedures. Repeat colonoscopy is likely to be considered when
the reason for the previous failure was inadequate bowel
preparation [34, 35]. On the other hand, radiological referral
appears most frequently indicated in the case of difficult
anatomy or patient intolerance [35]. Several studies [36–46]
have investigated CTC as a completion procedure following
incomplete colonoscopy. These studies show high technical
feasibility, a relatively high diagnostic yield, and an adequate
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positive predictive value (PPV), especially at a 10-mm thresh-
old. However, none of the studies employed an independent
reference standard for individuals with negative CTC find-
ings, so that the accuracy of CTC in this setting is unknown.
However, there is no apparent reason why the high accuracy
shown by CTC in both asymptomatic and symptomatic set-
tings, especially for large polyps or CRC, should not be
extrapolated to those individuals with incomplete colonosco-
py. For this reason, the superiority of CTC over barium enema
recently shown in a large randomized study [11] should favor
performance of CTC rather than barium enema following an
incomplete colonoscopy.
Timing of CTC after incomplete colonoscopy
CTC after incomplete colonoscopy requires a different ap-
proach from primary CTC.When endoscopic biopsy has been
done, CTC can be performed on the same day as the endo-
scopic procedure. An ultralow/low dose pre-CTC scan of the
abdomen and pelvis before insertion of the rectal tube may
rule out the presence of extraluminal gas that would indicate a
colonoscopic perforation. In detail, in 262 patients undergoing
CTC after incomplete colonoscopy, 2 perforations were de-
tected (0.8%, 95% confidence interval [95%CI] 0.1–2.7) [47].
In the case of endoscopic resection (i.e. polypectomy/
mucosectomy), it is prudent to consider an approximately 2-
week delay before performing CTC. However, there is little
scientific evidence concerning the interval between endoscop-
ic resection and subsequent CTC, thus for each case there
should be a clinical discussion between the endoscopist and
the radiologist. However, in a recent study on 65 CRC patients
with severe luminal narrowing after incomplete colonoscopy
with either polypectomy or biopsy sampling, no extraluminal
gas was detected at CTC within 24 hours [48]. Other evidence
for the safety of radiologic imaging after endoscopic biopsy
comes from barium enema studies, both experimental and
clinical [49–52]. These studies concluded that in a
nondiseased colon, barium enema could be performed imme-
diately after endoscopic biopsy without any risk. In the case of
endoscopic resection, barium enema could be performedwith-
out any risk after 6 days.
Incomplete colonoscopy due to obstructing CRC
Accurate preoperative assessment of the whole colon is re-
quired to exclude synchronous CRC. In a recent population-
based study of 13 683 Dutch patients diagnosed with CRC,
3.9% were diagnosed with synchronous CRC, and in 34% of
these cases the two tumors were located in different surgical
segments [53]. These data were in line with those from a
previous French study [54] and from other series [55]. Failure
to detect synchronous cancer can increase morbidity, and one
study has shown that intraoperative palpation can miss up to
69% of synchronous malignancies [56, 57]. Thus, preopera-
tive whole-colon assessment is needed.
CTC appears to be an effective and safe choice when
obstructing CRC prevents a complete endoscopic assessment
or when cecal intubation fails for other reasons. A recent study
including 286 CRC cases after failed colonoscopy showed
CTC negative predictive values (NPVs) of 100% and 97% for
synchronous cancer and advanced neoplasia, respectively, in a
preoperative setting [58]. This is in line with a previous
systematic review, showing equivalent sensitivity of colonos-
copy and CTC for established cancer [22], and in line with
findings from similar cohort studies [44, 59–63].
Patients with abdominal symptoms suggestive
of colorectal cancer
When endoscopy is contraindicated or not possible,
ESGE/ESGAR recommend CT colonography (CTC) as an
acceptable and equally sensitive alternative for patients with
symptoms suggestive of colorectal cancer (strong recom-
mendation, high quality evidence).
Patients with abdominal symptoms suggestive of colorectal
cancer (CRC) require detailed investigation, since neither
clinical examination nor fecal testing reliably excludes CRC
[64]. The ideal test would also diagnose non-neoplastic con-
ditions responsible for the symptoms (both within the colon
and beyond it). Patient acceptability and safety are also
important.
Colorectal neoplasia
In the SIGGAR trial no significant difference in the detection
rates for large polyps (≥10 mm) and for colorectal cancer was
demonstrated between CTC and colonoscopy [13]. Further-
more, the crude pooled sensitivity of CTC for colorectal
cancer in the studies of symptomatic patients was 96% (169
out of 176 colorectal cancers detected) [13]. This is compat-
ible with the 96.1% sensitivity of CTC for colorectal cancer
that was reported in a meta-analysis [22] that included both
screening and symptomatic/high risk patients. When large
polyps (≥10mm) only were considered, per-patient sensitivity
of CTC ranged from 82% to 92% in six meta-analyses that
included screening, symptomatic, high risk, and FOBT-
positive patients [19–21, 23, 25, 26]. In the studies specifically
investigating symptomatic patients, pooled sensitivity for
large ≥10-mm lesions (excluding cancers) was 91.4% (53 of
58 patients).
These data suggest that CTC and colonoscopy have similar
sensitivity for detecting CRC and large polyps in symptomatic
patients. Small polyps (6–9 mm) and diminutive polyps (≤5
mm) are less relevant in symptomatic patients, since they
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cannot explain the patient’s symptoms. Nonetheless, the abil-
ity to opportunistically detect and remove early precursor
lesions and perform histopathologic analysis of diagnosed
CRC remains a potential advantage of colonoscopy over
CTC.
Colorectal non-neoplastic disease
Abdominal symptoms may be due to non-neoplastic colonic
conditions, for which both CTC and colonoscopy may be
useful. Diverticulosis is more commonly demonstrated at
CTC than colonoscopy [13, 65], although the relationship
between diverticulosis and symptoms is less clear. Colonos-
copy is more sensitive for the detection of colitis and anal
pathology [13]; furthermore it offers the possibility of sam-
pling tissue.
Extracolonic findings
CTC is an abdominal CTexamination with the ability to detect
extracolonic diseases. Although these extracolonic lesions
may occasionally explain the symptoms, on the other hand,
incidental findings that ultimately prove unimportant may
prompt additional tests that are inconvenient, costly, and even
harmful. Few studies of extracolonic findings focus specifi-
cally on symptomatic patients, in whom there is a higher
prevalence of significant abnormality. The two largest series,
of screening [66] and symptomatic [11, 13] patients, respec-
tively reported 0.35% and 1.9% rates of extracolonic malig-
nancy. Importantly, in the paired SIGGAR trials, at 3-year
follow-up there was no significant difference in rates of
extracolonic malignancy between the two arms of each of
the trials (CTC vs. barium enema, and CTC vs. colonoscopy),
although all arms showed rates significantly above rates ex-
pected for the general population. The latter observation may
be explained by subsequent use of CT to investigate persistent
symptoms in patients randomized to colonoscopy or barium
enema, although this remains unproven.
CT colonography and screening for colorectal cancer
ESGE/ESGAR do not recommend CT colonography (CTC)
as a primary test for population screening or in individuals
with a positive first-degree family history of colorectal can-
cer (CRC). However, it may be proposed as a CRC screening
test on an individual basis providing the screenee is ade-
quately informed about test characteristics, benefits, and
risks (weak recommendation, moderate quality evidence).
Accuracy of computed tomography colonoscopy (CTC)
To date, only guaiac FOBT (g-FOBT) and sigmoidoscopy
have been shown to reduce CRC mortality, by 16% and
22%–31% respectively [67–69]. CTC has not been subjected
to randomized trials with CRC incidence or mortality as end
points. Therefore, the accuracy of CTC is used as a surrogate
end point for CTC efficacy in a screening setting.
CTC accuracy in average risk screening populations has
been investigated by a recent meta-analysis [24], which esti-
mated per-patient sensitivity at 88% for advanced neoplasia
≥10 mm. One further primary study published after this re-
view, showed similar results [16]. In six screening studies,
none of the 12 CRCs present were missed by CTC in average
risk individuals [14, 16–18, 70–72]. Individuals with a posi-
tive family history of CRC or adenomas should be considered
to be at high risk [73]. One recent cohort study showed a 89%
sensitivity of CTC for advanced neoplasia ≥10 mm in this
setting [74].
CTC in screening: participation and yield
The efficacy of a screening program not only depends on the
diagnostic accuracy of the screening test that is used, but also
on participation. This is illustrated by the results of a large
population-based randomized screening trial performed in the
Netherlands: participation rates for colonoscopy and CTC of
22% and 34%, respectively, were reported, and detection rates
for advanced neoplasia of 8.7 and 6.1 persons per 100 partic-
ipants, respectively [12]. Despite the higher sensitivity of
colonoscopy and the fact that CTC participants were only
referred to colonoscopy if they had lesions ≥10 mm detected
by CTC, the number of individuals per 100 invitees found to
have advanced neoplasia was similar for both screening mo-
dalities, namely 1.9 (colonoscopy) versus 2.1 (CTC) per 100
invitees [12]. The poorer sensitivity of CTC compared with
colonoscopy was countered by its approximately 1.5 times
higher participation rate.
In the case of serrated adenomas the diagnostic yield of
colonoscopy was 5 times higher than that of CTC. This is of
particular importance, since approximately 10%–20% of CRC
develops from the serrated pathway [75].
The diagnostic yield of CTC screening per 100 invitees
would appear to be significantly higher than the yield of first-
round g-FOBT, but similar to the yield of first-round flexible
sigmoidoscopy screening (2.2 per 100 invitees) and
fecal immunochemical testing (FIT) screening (2.0 per
100 invitees when using a cutoff of 50 ngHb/mL) [76].
One should however bear in mind that FOBT/FIT
screening is repeated at 2-year intervals, whereas 5–10-
year intervals are usually recommended for CTC and
endoscopic screening.
Eur Radiol (2015) 25:331–345 335
Acceptability of CTC screening
A recent meta-analysis included articles on preferences and
differences in burden for both average risk and high risk
individuals who had undergone CTC as well as colonoscopy
(tandem design) [77]. Amongst the included studies, 3573
patients reported a preference for CTC, 927 showed a prefer-
ence for colonoscopy, and 1116 showed no difference in
preference.
In a Dutch population-based screening trial, almost half of
the nonparticipants made an informed decision on participa-
tion as they were provided with adequate knowledge of CRC
and CRC screening, and showed a positive attitude towards
screening, but nevertheless declined participation, which sug-
gested that additional barriers to participation were present
[78]. The reasons cited for declining screening by colonosco-
py or by CTC were similar overall [79]. However, colonos-
copy invitees who declined most often mentioned ‘unpleas-
antness of the examination’ as their prime reason, while for
CTC invitees ‘no time/too much effort’ and ‘lack of symp-
toms’were most often cited. The last finding is consistent with
the findings of the study of Ho et al., in which 38% did not
participate in CTC screening because of procrastination and
12% because they were too busy [80].
As indicated above, most previous screening studies, using
a tandem design to compare perceived acceptability and bur-
den of the two techniques, showed a significant preference for
CTC, with 46% to 95% of participants preferring CTC for
future investigation [17, 81, 82].
A recent Netherlands study performed within the
population-based screening trial mentioned above showed
that colonoscopy invitees expected the screening procedure
and bowel preparation to be more burdensome than did CTC
invitees [83]. CTC participants in the Dutch study however
found their screening procedure slightly more burdensome
than did colonoscopy participants. Colonoscopy participants
gave higher burden scores to ingesting the bowel preparation,
while CTC participants gave higher burden scores to related
bowel movements (i.e. diarrhoea and bowel cramps). Al-
though these differences were statistically significant, they
were mostly small and thus the clinical relevance is limited
for a clinical population, but more significant for a primary
screening population. This is illustrated by the fact that
intended participation in a subsequent screening round
exceeded 90% for both colonoscopy and CTC.
Safety of CTC screening
Adverse events
The risk of major adverse events due to the CTC examination
itself (including the bowel preparation) is low and presumed
lower than for colonoscopy [13, 84]. Adverse events of CTC
screening, however, should include events related to the entire
episode, also including those related to any colonoscopy
required to investigate CTC findings (e.g. post-polypectomy
bleeding).
In a randomized trial comparing CTC with colonoscopy
screening, serious adverse events were comparable for both
procedures, (0.2% for CTC; 0.3% for colonoscopy) [12].
These rates are similar to adverse events observed in random-
ized trials of FOBT and of flexible sigmoidoscopy screening
[85]. In a recent meta-analysis [86] on 103 399 asymptomatic
and symptomatic patients, the CTC perforation rate was esti-
mated to be 0.04% overall; the rate was 19-fold higher in
symptomatic compared with screening individuals. The CTC-
induced surgery rate was 0.008% and no CTC-related deaths
were reported.
Radiation risk in screening
Radiation exposure at CTC is associated with a risk of cancer
induction. This risk is relevant for all individuals but especial-
ly so in screening where benefit should clearly outweigh
potential harm. The risk associated with ionizing radiation at
a single CTC is very small and has been estimated as an
absolute lifetime cancer risk of 0.14% for a 50-year-old and
0.07% for a 70-year-old, and can be reduced substantially with
protocol optimization [87]. Another study reported a less than
0.2% increase of the lifetime cancer risk in individuals under-
going CTC screening every 5 years between the ages of 50
and 80 years [88].
A study compared the anticipated cancer induced versus
anticipated cancer prevented by CTC screening using the
effective dose of a screening study (7 mSv for men and
8 mSv for women) [89]. In that study the radiation-related
lifetime cancer risk for a single screening CTC was 0.06% for
a 50-year-old person and decreased with age. The correspond-
ing calculated benefit–risk ratio for a 50-year-old person
ranged from 24:1 to 35:1 depending on the model used. A
recent international survey reported that the effective dose of
present day screening CTC was 4.4 mSv [90], which is lower
than used in the aforementioned study. Further dose reduction
is possible with technical developments such as iterative re-
construction algorithms and lower tube voltage, leading to
doses of 1 mSv [91].
Extracolonic findings
Extracolonic findings are common at screening CTC and have
been reported to occur in from one quarter to more than one
half of screenees [92–97]. The incidence of extracolonic find-
ings increases significantly with age; one study reported
extracolonic findings in 55.4% of screenees younger than
65years and in 74% of those 65 years or older [96]. The large
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majority of extracolonic findings are irrelevant and can be
classified as such at CTC.
Work-up for (potentially) important extracolonic findings
occurs in approximately 10% of cases [97–99]. The preva-
lence of extracolonic findings of moderate or high importance
at CTC is commonly reported to be approximately 10%–15%
of screenees [94, 95, 98, 99], although higher prevalence is
occasionally reported [92, 100]. This difference is partly
caused by variation in the definition of moderate and high
importance findings. The proportion of findings of high im-
portance is mostly in the order of 2%–5% [95, 97, 99], and
includes approximately 0.5% extracolonic cancers, of which
renal cell cancer, lung cancer and lymphoma are most preva-
lent [66, 97, 99, 100], and are usually localized at the time of
diagnosis [66]. Further important extracolonic findings in-
clude abdominal aortic aneurysms, adrenal masses, and non-
malignant renal masses.
The costs reported for the additional work-up of
extracolonic findings vary substantially and are influenced
by the definition of a relevant finding needing work-up and
by which costs are included. It appears that the average
additional cost for extracolonic findings at CTC is of the order
of 20–50 USD averaged over all attendees [94–96, 100, 101].
No studies report costs that might be saved by earlier detection
of disease.
CTC as a primary screening modality for CRC: conclusions
Primary CTC and colonoscopy screening have similar yields
for advanced neoplasia per invitee. However, the impact of
extracolonic findings, both medically and economically, re-
mains unknown. Although radiation exposure is a drawback,
this disadvantage seems to be overemphasised especially giv-
en the current reduction in radiation exposure with CTC.
Probably the most important factor is the question of whether
CTC screening is cost-effective, and this is still unanswered.
Based on these considerations, CTC cannot at this stage be
recommended as the primary test for population CRC screen-
ing or in individuals with a positive first-degree family history.
However, it may be suggested as a CRC screening test on an
individual basis, providing the screenees are adequately in-
formed about test characteristics, benefits, and risks.
CTC within a screening program, following positive fecal
testing with incomplete/unfeasible colonoscopy
ESGE/ESGAR strongly recommend CT colonography
(CTC) in the case of a positive fecal occult blood or fecal
immunochemical test with incomplete or unfeasible colo-
noscopy, within organized population screening programs
(strong recommendation, low quality evidence).
Repeated annual or biennial screening for colorectal cancer
(CRC) by guaiac-based fecal occult blood testing (FOBT)
reduces disease-specific mortality by approximately 15%–
18% [102]. Results of similar repeated screening by means of
fecal immunochemical testing (FIT) are awaited. It is assumed
that the impact on CRC-related mortality will be considerably
higher than with FOBT, because of the higher uptake of FIT
testing, and the higher sensitivity for advanced colorectal
lesions [103]. This is confirmed by modelling studies [104].
This benefit is contingent on confirmation and treatment of
underlying cancer or adenoma after a positive result. Colonos-
copy combines sensitive diagnosis with therapy by endoscopic
resection and is therefore regarded as the preferred test.
Since most screenees testing FOBT/FIT-positive will not
have advanced neoplasia, CTC has been investigated as a
possible triage test to select patients with lesions only of
greater size for colonoscopy or surgery. The sensitivity of
CTC for adenomas ≥6 mm was above 85% in six studies
[15, 25, 105–108] and was over 90% for adenomas ≥10
mm, a finding confirmed by a meta-analysis published after
our literature search [25]. A modelling study concluded that
the use of CTC as an intermediate after positive FOBT/FIT
can only be cost-effective if the costs of CTC were ≤43% of
the costs of colonoscopy [109]. Furthermore, despite sensitiv-
ity exceeding 85%, lesion prevalence is so high that NPV is
less than might be expected, ranging from 85% to 95% in the
studies included. These factors mean that CTC should not be
offered routinely to those testing FOBT/FIT-positive, and
colonoscopy is preferable.
Since CTC does have good diagnostic performance, it may
be considered for those unwilling to undergo colonoscopy or
in whom colonoscopy is unfeasible or incomplete, although
screenees should be informed that sensitivity (particularly for
smaller adenomas) is slightly inferior to that of colonoscopy.
There is some evidence that offering CTC to those who
decline colonoscopy increases uptake [110]. CTC is safe,
and therefore may be preferable in those with contraindica-
tions to colonoscopy or judged particularly high risk, although
observational data suggest absolute detection rates may be
lower than in healthy screenees who are fit for colonoscopy
[111]. Reasons for differences in detection rates are unknown
and only speculative at this stage. If the difference is con-
firmed, and if it is due to suboptimal CTC practice (CTC
technique and/or image interpretation), procedures for
guaranteeing high quality of CTC exams within organized
population screening programs will be necessary.
CT colonography and surveillance
Following curative-intent resection of colorectal cancer
ESGE/ESGAR suggest CT colonography (CTC) with intra-
venous contrast medium injection for surveillance after
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curative-intent resection of colorectal cancer only in patients
in whom colonoscopy is unfeasible (weak recommendation,
low quality evidence).
Patients with resected colorectal cancer are at a 30% risk of
recurrence [112, 113] which can be either colonic or
extracolonic. Local recurrence is less common for colonic
than rectal cancers [112, 114, 115]. Recurrence can occur
either at the site of anastomosis or near the site of the primary
resection. In contrast, metachronous lesions are colorectal
adenomas and cancers that develop subsequently to the index
cancer and do not originate from it. Extracolonic recurrent
disease comprises distant metastases in the liver, lung, perito-
neum, etc. CTC for postoperative surveillance following po-
tentially curative resection of colorectal carcinoma has the
potential to combine both colonic and extracolonic examina-
tion, and is therefore an alternative to combined optical colo-
noscopy and contrast-enhanced abdominal CT [116].
By means of a literature review, we identified eight cohort
studies investigating contrast-enhanced CTC as a surveillance
tool after resection of colorectal cancer [116–123]. All of these
studies demonstrated a high technical feasibility.
Local recurrence and metachronous colorectal cancer
In these studies, all local recurrent (n = 65) and metachronous
(n = 9) colonic cancers, were detected [116–123]. The largest
study included 548 patients who had subsequent colonoscopy
and pathologic confirmation of colonic lesions [116]. CTC
sensitivity for anastomotic and metachronous recurrence was
100%. Per-patient and per-lesion sensitivities for advanced
neoplasia were 81.8% and 80.8%, respectively, and for all
adenomatous lesions they were 80.0% and 78.5%, respective-
ly [116]. NPVs for adenocarcinoma, advanced neoplasia, and
all adenomatous lesions were 100%, 99.1%, and 97.0%, re-
spectively. CTC enabled detection of clinically unsuspected
metastatic disease in 11 patients, none of them having a
cancerous lesion in the colon [116].
CTC surveillance detection of adenoma/polyp
In a study on 548 consecutive patients, without clinical or
laboratory evidence of recurrence following curative-intent
CRC, who underwent contrast-enhanced CTC and subsequent
colonoscopy and pathologic confirmation of colonic lesions,
CTC sensitivity for all adenomas of 80.0% (per-patient) and
78.5% (per-lesion) were reported [116]. Unfortunately, accu-
racy data for these lesions cannot be extracted from the other
studies, because of the low number of patients with polypoid
lesions, inconsistent or insufficient reporting on the detection/
presence of polyps/adenomas, and/or lack of histological
polyp data that impeded any stratification and comparison of
results [117–123].
CTC following polypectomy
ESGE/ESGAR suggest CT colonography (CTC) in patients
with high risk polyps in surveillance after polypectomy only
when colonoscopy is unfeasible (weak recommendation, low
quality evidence).
The recent ESGE Guideline recommends endoscopic
surveillance only for patients with high risk adenomatous
lesions (adenomas with villous histology or high grade
dysplasia or ≥10 mm in size, or ≥3 adenomas) or serrated
lesions (≥10 mm in size, or any degree of cytological
dysplasia) [124]. Colonoscopy is considered to be the
method of choice for post-polypectomy surveillance,
whose primary aim is to diagnose and remove polyps
either missed at initial examination or newly developed
during the time interval between the index and follow-up
examination. However, compliance with colonoscopic
surveillance is relatively low, ranging from 52% to 85%,
with the highest levels obtained in research settings
[125–128]. Despite weak evidence supporting CTC for
surveillance [15], in patients who are unwilling or unable
to undergo colonoscopy, CTC is the best alternative
because of its high sensitivity and NPV, outperforming
barium enema [11, 22, 29].
Safety of CT colonography
ESGE/ESGAR state that CTcolonography (CTC) is contrain-
dicated in patients with active colonic inflammation and in
those who have recently undergone colorectal surgery (strong
recommendation, low quality evidence).
Despite being generally regarded as safer than colonoscopy
[129], CTC has been shown to be associated with potentially
serious adverse events, in particular perforation of the large
bowel [130, 131]. Acute abdominal conditions, for example
diverticulitis or active inflammatory bowel disease (IBD), are
absolute contraindications to CTC, because of the relatively
high risk of complication [132], and CTC should be avoided
[130]. Unfortunately, there are few studies supporting these
strong recommendations. In a recent meta-analysis [86] in-
cluding more than 100 000 individuals, 28 colonic perfora-
tions were reported. Moreover, eight case reports – not includ-
ed in the meta-analysis – detail CTC perforation [133–140].
These reports allow identification of some risk factors for
perforation. Among the 36 patients with perforation, four
(11%) were affected by inflammatory bowel diseases, four
had a known inguinal hernia, and in one case the perforation
occurred after erroneous inflation of a rectal stump.Moreover,
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mural frailty during active inflammation or in the postopera-
tive setting suggests that any procedure involving colonic
distension entails a risk.
Colonoscopy following CT colonography
ESGE/ESGAR recommend referral for endoscopic
polypectomy in patients with at least one polyp ≥6 mm in
diameter detected at CT colonography (CTC). CTC surveil-
lance may be clinically considered if patients do not undergo
polypectomy (strong recommendation, moderate quality
evidence).
Polyp size and risk of advanced neoplasia
Diminutive polyps (≤5 mm)
Most colorectal lesions encountered at endoscopy are polyps
<5 mm (i.e. diminutive) [141]. However, only a small propor-
tion of these lesions meet histological criteria for advanced
neoplasia. In detail, a recent systematic review of 28 947
polyps found the frequency of advanced neoplasia to be
1.4% (408/28 947), while the risk of invasive cancer was
0.03% (10/31 263) [142]. Little information is available re-
garding the natural history of untreated ≤5-mm polyps. In two
prospective Northern European endoscopic studies, Hoff et al.
[143] and Hofstad et al. [144] followed up 194 diminutive and
253 ≤9 mm polyps for 2 and 3 years, respectively. No dimin-
utive polyp reached >5 mm in size and only 0.5% of polyps
≤10 mm exceeded the 10-mm threshold after 1 year; no cases
of severe dysplasia or carcinoma were reported [143, 144].
Similar findings were reported by a Japanese study, in which
only 2.9% of 408 subcentimetric lesions followed up for 43.1
months reached ≥10 mm size, without any invasive cancer
occurring [145].
Small polyps (6–9 mm)
Overall, polyps of 6–9 mm (i.e. small polyps) represent about
15% of all the polyps detected during primary screening
colonoscopy [141]. In a recent systematic review of 8605
polyps, the frequency of advanced neoplasia was 7.9%, while
the proportion with invasive cancer was 0.5% (10/8456]
[142]. A retrospective analysis of 5124 individuals undergo-
ing screening CTC confirmed a very low risk of advanced
neoplasia and invasive cancer in 464 patients with polyps 6–
9mm in size as the largest lesion, corresponding to a 3.9% and
0% risk, respectively [146].
Recently, the natural history of 6–9-mm polyps detected at
CTC was addressed by a longitudinal study. Specifically, 243
adults with 306 small polyps detected by CTC underwent a
second CTC after a 2–3-year follow-up [147]. Overall, 22%
polyps had progressed, with 6% exceeding 10 mm. The odds
ratio was 16 for advanced adenoma among polyps that had
shown growth during surveillance compared with advanced
adenoma among 6–9-mm polyps detected and removed at
initial CTC and colonoscopy in a reference cohort. An abso-
lute polyp volume of more than 180 mm3 at surveillance CTC
was shown to predict advanced neoplasia (including one
cancer) with a sensitivity of 92% (22 of 24 polyps), specificity
of 94% (266 of 282 polyps), PPVof 58% (22 of 38 polyps),
and NPVof 99% (266 of 268 polyps).
Recently, factors that may predict advanced neoplasia
within a subcentimeter polyp have been investigated.
Kolligs et al. [148] applied a logistic regression model
to a large retrospectively obtained cohort of 1 077 956
colonoscopies, in which 106 270 small and 198 954
diminutive lesions were removed. The risk of advanced neo-
plasia within subcentimetric lesions was associated with in-
creasing age, male sex, polyp morphology, polyp multiplicity,
and occult or overt blood in the stools.
Large polyps (≥10 mm) and masses
Overall, ≥10-mm polyps (i.e. large polyps) represent about
10% of all polyps detected during primary screening colonos-
copy [141]. In a previous systematic review, 73.5%
(1363/1855) of these polyps appeared to be advanced adeno-
mas, the remainder being nonadenomatous [141]. The preva-
lence of invasive cancer has been recently addressed in large
colonoscopic and CTC screening series, with reported ranges
between 2% and 7% [146, 148, 149].
Same-day polypectomy
ESGE/ESGAR suggest same-day polypectomy as a possible
option after CTcolonography (CTC) performed with full bowel
preparation. The implementation of this policy should take into
account technical and logistical factors, including patient con-
sent (weak recommendation, low quality evidence).
Type of laxative used for CTC
Bowel preparation for CTC usually includes a low residue diet
and clear liquids for 24 hours or more, and a laxative prepa-
ration that may be either a “wet prep” (e.g. polyethylene
glycol [PEG]) or “dry prep” (e.g. phosphosoda, magnesium
citrate, etc). In the studies identified in the literature search for
CTC and same-day colonoscopy, a range of different prepa-
rations was used, with approximately half using PEG, and the
remaining using phosphosoda or a similar laxative. The ratio-
nale for laxative choice was rarely stated, although some
studies documented that choice was based on that routinely
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used for colonoscopy by the host institution. Furthermore,
although data were sometimes presented on quality of CTC
preparation, few studies formally graded bowel cleansing
during same-day colonoscopy.
One large study of same-day CTC and colonoscopy
in 734 patients [105], investigated the quality of CTC
imaging according to the CT Colonography Reporting
and Data System (C-RADS) and graded the quality of
bowel preparation at colonoscopy. Patients were pre-
pared before CTC, with clear liquid during the preced-
ing 24 hours, 30 ml sodium phosphate and 20 mg
bisacodyl as laxatives, and oral barium and iodine
agents for tagging. Only 3.1% of the procedures were
classified as inadequate for CTC interpretation; in 20 of
23 cases this was due to insufficient insufflation. At colonos-
copy, colonic preparation was classified by the endoscopist as
excellent or good in 63% of patients, fair in 28%, poor in
8.5%, and inadequate in 0.5%.
A minority of studies commented regarding the quality of
preparation during colonoscopy, but provided little detailed
information.
The fact that the literature is so sparse regarding quality of
preparation during same-day colonoscopy does suggest that it
is not a major issue. However it cannot be determined from the
available literature which bowel preparation is preferred for
same-day colonoscopy after CTC. Although the frequency
and extent of retention of fecal material and fluids at CTC
has been extensively studied, the effects of the various CTC
preparation protocols on the performance of same-day colo-
noscopy is less well known.
Laxative-free CTC
Reduced bowel preparations at CTC are gaining popularity
but may prevent same-day endoscopy (although minor fecal
residue may be suctioned during colonoscopy). Our literature
search found no information regarding the quality of same-
day colonoscopy after same-day laxative-free CTC. However
several studies have reported using additional bowel cleansing
subsequent to laxative-free CTC when same-day colonoscopy
is required. For example, in a study of 95 symptomatic pa-
tients undergoing reduced-laxative CTC, senna and 18 g mag-
nesium citrate were used, with an additional 18 g of
magnesium citrate after CTC but prior to colonoscopy
[150]. Lefere et al. [151] compared standard bowel
preparation, reduced bowel preparation, and oral barium
for fecal tagging in 100 patients having CTC with
same-day colonoscopy. In order to compensate for re-
duced bowel purgation, which may prohibit colonoscopy,
PEG was administered after CTC, and colonoscopy per-
formed 2–3 hours later.
Fecal tagging
Fecal tagging with oral barium or hyperosmolar/iso-osmolar
iodine solutions or both is now consideredmandatory for CTC
[7]. Occasionally, concern has been raised that when barium is
used, it may interfere with the diagnostic quality of same-day
colonoscopy, potentially obscuring the endoscopic view by
coating the colonic mucosa. Others have suggested that
retained barium and iodine-based contrast agents are easily
aspirated or flushed out of the way during endoscopy, and
therefore are of no concern. Our literature search, including
studies of same-day CTC and colonoscopy with or without fecal
tagging, found little specific information on this issue. Frequen-
cy of incomplete colonoscopy was commonly cited, indicating
causes such as tortuous bowel, pain, or strictures, but problems
specifically related to fecal tagging were rarely mentioned.
Pickhardt et al. [18] analyzed 1233 asymptomatic
patients undergoing CTC (with fecal and fluid tagging)
and same-day colonoscopy with segmental unblinding.
The quality of bowel preparation was not formally re-
ported but only six of 1253 patients were excluded
initially because of inadequate colonic preparation. Sub-
optimal colonoscopy quality was dismissed as a reason
for missed adenomas since the colonoscopy completion
rate was high at 99.4%.
A similar tagging regimen was used in another large study,
mentioned above, of same-day CTC and colonoscopy in
a population at average or high risk of colorectal cancer
[105]. The quality of CTC imaging was assessed by the
radiologist according to the C-RADS system and the
quality of bowel preparation at colonoscopy was graded
by the endoscopist on a 5-point scale, from excellent to
inadequate. At colonoscopy, 63% of cases were classified
as excellent or good, 28% as fair, 8.5% as poor and 0.5%
as inadequate. At CTC, 23 (3.1% of the cases) cases
were classified as C0, which includes preparation or
insufflation that is inadequate for satisfactory interpreta-
tion; as noted above, 20 of the 23 cases were due to
inadequate insufflation. These 23 cases were classified at
colonoscopy as having excellent or good preparation in
65%, fair in 30%, and poor or inadequate in 5%. There
was no mention that tagging agents were a complicating
factor at colonoscopy.
It can therefore be inferred indirectly from the relatively
large number of comparative same-day CTC and conventional
colonoscopy studies aimed at diagnostic accuracy, that fecal
tagging likely does not negatively affect colonoscopy results.
Logistics of same-day colonoscopy
To provide same-day endoscopy after CTC, the indications
and logistics concerning patient selection, timing, patient
transportation, availability of endoscopists and endoscopy
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suites etc. must be pre-planned jointly by radiology and en-
doscopy units. This modality also requires that CTC findings
are reviewed by a radiologist immediately in order to identify
patients in whom same-day colonoscopy is needed, and in
order to identify the rare but well-recognised perforations that
occur during CTC.
When a lesion detected at CT colonography (CTC) is not
confirmed by a high quality colonoscopy, ESGE/ESGAR rec-
ommend careful review of the CTC findings. In cases when
post-colonoscopy radiological confidence for the presence of
a ≥10-mm lesion remains high, early repetition of colonosco-
py should be considered (weak recommendation, low quality
evidence).
It is possible that colorectal lesions reported at CTC may
not be detected at colonoscopy, either because they are CTC
false positives or colonoscopic false negatives. Clinical con-
sequences include progression of colonoscopic false-negative
polyps towards invasive CRC or anxiety due to CTC false-
positive findings. In a recent prospective multicenter study of
symptomatic patients, the PPV of CTC for large polyps was
about 60%, indicating that colonoscopic inability to confirm
CTC findings occurs frequently [11]. The sensitivity of colo-
noscopy for >10-mm polyps is higher [152], and may
be presumed to be substantially increased when – as
occurs in daily practice – the endoscopist is searching
specifically for a CTC finding. Therefore, the possibility
of missing large lesions at such colonoscopies may be
considered too low to warrant a further endoscopic examina-
tion. However, it is well known that colonoscopy is not 100%
sensitive even for large lesions that are present at CTC, a
phenomenon that has been explained by the existence of
colonoscopic “blind spots” [153]. Most post-colonoscopic
interval cancers are related to missed rather than new lesions.
In contrast to 6–9-mm polyps, the risk of established cancer in
larger lesions is relevant [149]. Thus if, after negative colo-
noscopy findings, confidence in the CTC diagnosis remains
high, an early repetition of colonoscopy should be considered,
especially if the abnormality appears to be related to flexures
or to be on the proximal side of colonic haustra.
ESGE guidelines represent a consensus of best practice based
on the available evidence at the time of preparation. They may
not apply in all situations and should be interpreted in the light of
specific clinical situations and resource availability. Further
controlled clinical studies may be needed to clarify aspects of
these statements, and revision may be necessary as new data
appear. Clinical consideration may justify a course of action at
variance to these recommendations. ESGE guidelines are
intended to be an educational device to provide information that
may assist endoscopists in providing care to patients. They are
not rules and should not be construed as establishing a legal
standard of care or as encouraging, advocating, requiring, or
discouraging any particular treatment.
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